# ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma

> **NCT01219790** · PHASE1 · COMPLETED · sponsor: **Institut Cancerologie de l'Ouest** · enrollment: 30 (actual)

## Conditions studied

- Prostate Adenocarcinoma

## Interventions

- **RADIATION:** external radiotherapy
- **DRUG:** Acide zoledronic

## Key facts

- **NCT ID:** NCT01219790
- **Lead sponsor:** Institut Cancerologie de l'Ouest
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2014-11
- **Final completion:** 2015-11
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01219790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01219790, "ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01219790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*